8 citations
,
August 2016 in “Journal of Cutaneous Pathology” Scalp biopsies are crucial for diagnosing hair loss causes in cutaneous lymphoma patients.
October 2025 in “Cell Death and Disease” CD271 is crucial for maintaining healthy skin and preventing inflammation.
5 citations
,
May 2024 in “Developmental Cell” Lower GATA3 levels in mice help hair regrow by changing certain immune cells.
6 citations
,
May 2002 in “British journal of dermatology/British journal of dermatology, Supplement” A rare skin condition linked to leukemia improved with chemotherapy.
November 2021 in “Authorea (Authorea)” PRP treatments and hair transplantation may be linked to the progression of pseudolymphoma to lymphoma.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
1 citations
,
October 2023 in “European Journal of Dermatology” Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
December 2025 in “Meditsinskiy sovet = Medical Council” Early diagnosis and multidisciplinary care are crucial for managing CNOT3 syndrome.
3 citations
,
April 2012 in “Cancer research” Mouse skin cancer progression involves a unique group of cells marked by ABCG2 and MTS24.
3 citations
,
June 2023 in “Modern Pathology” GLI1 RNA CISH effectively identifies basal cell carcinoma but is less specific for benign follicular tumors.
68 citations
,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
January 2026 in “Human Mutation” T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.
1 citations
,
September 2024 in “Porto Biomedical Journal” Early and accurate diagnosis of primary vitreoretinal lymphoma is crucial to prevent serious complications.
39 citations
,
September 2007 in “BMC developmental biology” Neuregulin3 affects cell development in the skin and mammary glands.
August 2024 in “Case Reports in Ophthalmology” Older patients with new retinal lesions may have cancer, and local radiation might not stop it from spreading.
8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
July 2019 in “Cancer Research” Bone marrow and hair follicle cells help form skin tumors, suggesting new treatment targets.
Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.
April 2023 in “Journal of Investigative Dermatology” CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.
Scalp involvement in primary cutaneous lymphomas is common and can be aggressive, requiring careful attention.
October 2023 in “Pediatric blood & cancer” Thymic LCH may be underdiagnosed, so thymic ultrasound should be considered in infants with cutaneous LCH.
April 2017 in “Journal of Dermatological Science” B cells can both help and hinder the body's defense against melanoma.
10 citations
,
August 2016 in “Oxford Medical Case Reports” Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
April 2012 in “Cancer Research” Bone marrow-derived cells can lead to skin inflammation and tumors in mice.
April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
January 2026 in “Journal of Dermatological Science” DcR3 helps heal wounds and regrow hair by changing macrophages to a repair-focused type.
November 2025 in “Journal of Investigative Dermatology” Certain immune cells in atopic dermatitis skin could be targeted for treatment.
1 citations
,
January 2023 in “Indian Dermatology Online Journal” Skin and nail changes are common in patients with blood cancers undergoing chemotherapy, affecting their quality of life.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.